NEW YORK (GenomeWeb) – Australian molecular diagnostics manufacturer Genetic Signatures recently launched a line of analyte-specific reagents in the US and collaborated with the University of California, Los Angeles to evaluate a multiplex panel assay for enteric protozoan infections with an eye toward regulatory approval and the US diagnostics market.
Genetic Signatures Launches Analyte-Specific Reagents in US; Eyes FDA Approval for MDx Panels
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.